HA
KYNB

HHLR Advisors’s Kyntra Bio KYNB Stock Holding History

HHLR Advisors’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-158,231
Closed -$105M – 93
2021
Q2 		$105M Hold
158,231
– – 1.08% 22
2021
Q1 		$137M Hold
158,231
– – 1.36% 18
2020
Q4 		$147M Hold
158,231
– – 1.17% 18
2020
Q3 		$163M Hold
158,231
– – 1.23% 16
2020
Q2 		$160M Hold
158,231
– – 1.47% 14
2020
Q1 		$137M Hold
158,231
– – 1.85% 14
2019
Q4 		$170M Buy
158,231
+18,100
+13% +$18.5M 2.11% 14
2019
Q3 		$130M Buy
140,131
+31,150
+29% +$34.2M 1.78% 16
2019
Q2 		$123M Buy
108,981
+28,850
+36% +$31.6M 2.75% 15
2019
Q1 		$109M Hold
80,131
– – 3.03% 10
2018
Q4 		$92.7M Buy
+80,131
New +$90.1M 3.85% 7

Other funds holding KYNB

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

HHLR Advisors's KYNB Position: Q3 2021 in Review

HHLR Advisors sold out of Kyntra Bio (KYNB) in Q3 2021, closing a stake of 158,231 shares — an estimated $105M sold.

HHLR Advisors first reported a position in KYNB in Q4 2018 and held it in 11 quarters. The position peaked at $170M in Q4 2019. 164 funds tracked by Wall St. Rank hold KYNB as of Q3 2021.

  • HHLR Advisors reported no remaining Kyntra Bio position as of Q3 2021 after selling out during the quarter.
  • HHLR Advisors sold 158,231 Kyntra Bio shares in Q3 2021, an estimated $105M.
  • HHLR Advisors first reported a position in Kyntra Bio in Q4 2018 and held it in 11 quarters.
  • HHLR Advisors's Kyntra Bio position peaked at $170M in Q4 2019.
  • 164 funds tracked by Wall St. Rank held Kyntra Bio as of Q3 2021.

Based on HHLR Advisors's 13F filing for Q3 2021, filed 15 Nov 2021.